Actively Recruiting
Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
Led by Avistone Biotechnology Co., Ltd. · Updated on 2025-05-21
156
Participants Needed
1
Research Sites
185 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Efficacy and Safety Evaluation of Vebreltinib Plus PLB1004 in EGFR TKI Relapsed MET Amplified or MET Expression in NSCLC
CONDITIONS
Official Title
Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Ability to understand and willing to sign informed consent
- At least 18 years old
- Histologically or cytologically confirmed locally advanced or metastatic NSCLC (stage IIIB to IV)
- Presence of EGFR mutations including exon 19 deletion or exon 21 L858R
- MET overexpression and/or amplification confirmed after EGFR-TKI treatment
- At least one measurable lesion per RECIST V1.1
- ECOG performance status of 0 to 1
You will not qualify if you...
- Previous treatment with MET inhibitors or HGF-targeted therapy
- Presence of ALK or ROS1 mutations
- Symptomatic and neurologically unstable CNS metastases or CNS disease requiring increased steroid doses
- Pregnant or nursing women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China, 200433
Actively Recruiting
Research Team
L
Liang Lin
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here